Knowledge Hub

Add resource

8472 matches found

P6-5 EuBiologics’s Vaccine Technologies for Equity

Global initiatives

P6-4 Single Injection Vaccines

Global initiatives

P6-2 The Vaccine Innovation Prioritisation Strategy (VIPS): driving innovations to improve vaccine delivery in low- and middle-income countries

Global initiatives

W9-4 Use of Social data to inform programmatic action for COVID-19 vaccine uptake in Nigeria

Global initiatives Nigeria COVID-19

W9-3 Applying Social Science & Behavioural Design in Development and Humanitarian settings: Middle East & North Africa

Global initiatives Africa

W9-2 Vaccine uptake and equity: How to understand and address low uptake

Global initiatives

W9-1 Understanding and addressing behavioural and social drivers

Global initiatives

P5-2 Mapping the distribution of zero-dose children and their characteristics in low- and middle-income countries

Global initiatives

P5-1 Introduction to Zero-Dose

Global initiatives

P4-4 A Pathway to Impact: Exploring the potential of measles rubella microarray patches to reach zero dose children and improve measles vaccine coverage through an initial Full Value Vaccine Assessment

Global initiatives Rubella Measles

P4-3 The Full Vacccine Accessment for Group A Streptococcus Vaccines

Global initiatives

P4-2 Using the FVVA framework to estimate the potential health and economic impacts of novel TB vaccines in low- and middle-income countries

Global initiatives TB

P4-1 The Full Value of Vaccines Assessment (FVVA) concept

Global initiatives

P3-5 Current Status of Universal Influenza Vaccine Research and Development

Global initiatives Influenza

P3-4 HIV Vaccine Update

Global initiatives HIV-AIDS

P3-3 Tuberculosis Vaccine R&D

Global initiatives TB

P3-1 Introduction: Current status of vaccine R&D for HIV, Tb, Malaria, and Universal flu

Global initiatives TB Malaria Influenza HIV-AIDS

KN1 Vaccines in the post-COVID era: Can policy and practice keep up with science?

Global initiatives

WHO SAGE roadmap on uses of COVID-19 vaccines in the context of OMICRON and substantial population immunity

Vaccines & delivery devices COVID-19

P2-5 Lessons learned from an industry R&D perspective

Global initiatives COVID-19

Filters